125 related articles for article (PubMed ID: 35632406)
1. Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers.
Niekrens V; Esse J; Held J; Knobloch CS; Steininger P; Kunz B; Seggewies C; Bogdan C
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632406
[TBL] [Abstract][Full Text] [Related]
2. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
5. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
[TBL] [Abstract][Full Text] [Related]
6. Health Care Workers' Sick Leave due to COVID-19 Vaccination in Context With SARS-CoV-2 Infection and Quarantine-A Multicenter Cross-Sectional Survey.
Bauernfeind S; Huppertz G; Mueller K; Hitzenbichler F; Hardmann L; Pemmerl S; Hollnberger H; Sieber W; Wettstein M; Seeliger S; Kienle K; Paetzel C; Kutz N; Daller D; Zorger N; Mohr A; Lampl BMJ; Salzberger B
Open Forum Infect Dis; 2022 Jul; 9(7):ofac203. PubMed ID: 35791359
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy.
Rahmani A; Dini G; Orsi A; Sticchi L; Bruzzone B; Montecucco A; Pellegrini L; Manca A; Domnich A; Battistini A; Kusznir Vitturi B; Zacconi S; Debarbieri N; Icardi G; Durando P
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835199
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
9. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine.
Levy I; Levin EG; Olmer L; Regev-Yochay G; Agmon-Levin N; Wieder-Finesod A; Indenbaum V; Herzog K; Doolman R; Asraf K; Halperin R; Lustig Y; Rahav G
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016109
[TBL] [Abstract][Full Text] [Related]
10. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study.
Kang YM; Lim J; Choe KW; Lee KD; Jo DH; Kim MJ; Kim JM; Kim KN
Clin Exp Vaccine Res; 2021 Sep; 10(3):282-289. PubMed ID: 34703812
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
12. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
14. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
15. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: Vaccination Side Effects and Sick Leave in Frontline Healthcare-Workers-A Web-Based Survey in Germany.
Nohl A; Brune B; Weichert V; Standl F; Stang A; Dudda M
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335043
[TBL] [Abstract][Full Text] [Related]
18. Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population.
Tabatabaeifar S; Vestergaard JM; Würtz ET; Hansen KK; Nielsen KJ; Schlünssen V; Kolstad HA
Vaccine X; 2023 Apr; 13():100280. PubMed ID: 36945661
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
Held J; Esse J; Tascilar K; Steininger P; Schober K; Irrgang P; Alsalameh R; Tenbusch M; Seggewies C; Bogdan C
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
